NAN Nanoscience

    Embargoed Release: 07:00hrs Thursday 24 January 2008

                               Nanoscience Inc.                                

                                 (`The Group')                                 

          Toumaz Technology Awarded ISO 13485 Medical Device Quality           

              Management Certification for Sensium(tm) Wireless Body              

                              Monitoring Platform                              

  Toumaz's commitment to the highest quality management standard required for  
     medical device manufacture recognised by independent accrediting body     

Nanoscience Inc, the specialist niche investor in emerging technologies with
strong commercial propositions from within the growing nanotechnology sector,
is pleased to announce that its wholly owned subsidiary Toumaz Technology
Limited (`Toumaz') has received ISO 13485:2003 certification for its quality
management system. ISO 13485 is the regulatory standard for the international
medical industry and is closely related to ISO 9000. Toumaz (a leading provider
of ultra-low power wireless infrastructure for body monitoring solutions) was
assessed and certified as meeting the requirements of this strategically
significant standard by independent body SGS, the world's leading verification
and certification body.

ISO 13485 is a regulatory requirement in a number of international markets for
the manufacture of medical devices, and forms the cornerstone for the CE
certification of medical products in the EU. Meeting the ISO quality management
standard is a crucial milestone in the ongoing commercialisation of Sensium(tm),
Toumaz's breakthrough ultra-low power wireless platform for the development of
non-intrusive body monitors for healthcare and lifestyle markets. In November
2007, Toumaz took the top honours in the Electronics category of the
prestigious Innovation in Engineering Awards - given by The Institution of
Engineering and Technology - in recognition of the groundbreaking innovation of
the Sensium as an enabling technology for highly valuable medical applications.

Keith Errey, COO, Toumaz, commented:

"We are delighted that Toumaz has been awarded the important ISO 13485
certification, which demonstrates our absolute commitment to quality throughout
the product cycle including the manufacture of medical devices, and which will
offer significant benefits to our customers."

The unique combination of ultra-low power wireless and signal processing in one
small System-on-Chip (SOC) allows the economies of scale of the semiconductor
industry to be harnessed to provide highly functional, robust, low cost,
disposable and non-intrusive monitors for a wide range of healthcare
applications.

The Sensium sensor interface and transceiver platform enables real-time,
intelligent, ultra-low power wireless monitoring of multiple vital signs - such
as ECG, heart rate, body temperature, respiration and physical activity (via a
3-axis accelerometer) - and is currently being developed in both disposable and
non-disposable body monitoring products.

 

                                   - Ends -                                    

About Toumaz Technology (www.toumaz.com)

Toumaz Technology Limited is the leading provider of ultra-low power wireless
infrastructure for body monitoring solutions.

Toumaz's ultra low-power smart sensor interface and transceiver platform - the
Sensium(tm) - enables non-intrusive, real-time wireless monitoring of multiple
vital signs for a wide range of healthcare and lifestyle management
applications. Based on Toumaz's patented ultra-low power Advanced Mixed Signal
(AMx)(tm) technology, the Sensium provides the enabling technology to connect the
mobile individual to healthcare providers - simply, affordably and
unobtrusively.

For healthcare professionals, this transforms the possibilities for pro-active
monitoring and improved quality of care. For patients, it delivers new
opportunities for lifestyle-compatible, personalised healthcare, as well as
better therapeutic outcomes.

Further information:

Guy Spelman               Nanoscience Inc.          07767 338 967            
                                                                             
Andrew Tan                Hansard Group             020 7245 1100            
                                                                             
www.hansardgroup.co.uk                                                       
                                                                             
Tim Goodman               Ambrian Partners Limited  0207 776 6400            

About Nanoscience Inc.:

Nanoscience is a specialist niche investor in emerging technologies with a
strong commercial proposition from within the medical technology and
semiconductor sectors.



END

Nanoscience (LSE:NAN)
Historical Stock Chart
From Dec 2024 to Jan 2025

Nanoscience (LSE:NAN)
Historical Stock Chart
From Jan 2024 to Jan 2025